Kehl Sue C, Dowzicky Michael J
Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Pfizer Inc., Collegeville, Pennsylvania, USA.
J Clin Microbiol. 2015 Apr;53(4):1286-93. doi: 10.1128/JCM.03184-14. Epub 2015 Feb 4.
The Tigecycline Evaluation and Surveillance Trial (TEST) was designed to monitor susceptibility to commonly used antimicrobial agents among important pathogens. We report here on susceptibility among Gram-negative pathogens collected globally from pediatric patients between 2004 and 2012. Antimicrobial susceptibility was determined using guidelines published by the Clinical and Laboratory Standards Institute (CLSI). Most Enterobacteriaceae showed high rates of susceptibility (>95%) to amikacin, tigecycline, and the carbapenems (imipenem and meropenem); 90.8% of Acinetobacter baumannii isolates were susceptible to minocycline, and susceptibility rates were highest in North America, Europe, and Asia/Pacific Rim. Amikacin was the most active agent against Pseudomonas aeruginosa (90.4% susceptibility), with susceptibility rates being highest in North America. Extended-spectrum β-lactamases (ESBLs) were reported for 11.0% of Escherichia coli isolates and 24.2% of Klebsiella pneumoniae isolates globally, with rates reaching as high as 25.7% in the Middle East and >43% in Africa and Latin America, respectively. Statistically significant (P<0.01) differences in susceptibility rates were noted between pediatric age groups (1 to 5 years, 6 to 12 years, or 13 to 17 years of age), globally and in some regions, for all pathogens except Haemophilus influenzae. Significant (P<0.01) differences were reported for all pathogens globally and in most regions, considerably more frequently, when pediatric and adult susceptibility results were compared. Amikacin, tigecycline, and the carbapenems were active in vitro against most Gram-negative pathogens collected from pediatric patients; A. baumannii and P. aeruginosa were susceptible to fewer antimicrobial agents. Susceptibility rates among isolates from pediatric patients were frequently different from those among isolates collected from adults.
替加环素评估与监测试验(TEST)旨在监测重要病原体对常用抗菌药物的敏感性。我们在此报告2004年至2012年间从全球儿科患者中收集的革兰氏阴性病原体的药敏情况。抗菌药物敏感性依据临床和实验室标准协会(CLSI)发布的指南确定。大多数肠杆菌科细菌对阿米卡星、替加环素和碳青霉烯类药物(亚胺培南和美罗培南)显示出较高的敏感性(>95%);90.8%的鲍曼不动杆菌分离株对米诺环素敏感,北美、欧洲和亚太地区的敏感性率最高。阿米卡星是对铜绿假单胞菌最有效的药物(敏感性为90.4%),北美地区的敏感性率最高。全球范围内,11.0%的大肠杆菌分离株和24.2%的肺炎克雷伯菌分离株报告产超广谱β-内酰胺酶(ESBLs),中东地区该比例高达25.7%,非洲和拉丁美洲分别超过43%。除流感嗜血杆菌外,全球和部分地区所有病原体在不同儿科年龄组(1至5岁、6至12岁或13至17岁)之间的药敏率存在统计学显著差异(P<0.01)。全球和大多数地区报告称,当比较儿科和成人药敏结果时,所有病原体都存在显著差异(P<0.01),且差异更为频繁。阿米卡星、替加环素和碳青霉烯类药物在体外对从儿科患者中收集的大多数革兰氏阴性病原体具有活性;鲍曼不动杆菌和铜绿假单胞菌对较少的抗菌药物敏感。儿科患者分离株的药敏率通常与成人分离株不同。